aTyr Pharma, Inc. (NASDAQ:LIFE) has been assigned a consensus recommendation of “Hold” from the six ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $5.06.

A number of equities research analysts recently weighed in on the stock. Zacks Investment Research cut shares of aTyr Pharma from a “buy” rating to a “hold” rating and set a $5.25 price target for the company. in a research report on Thursday. ValuEngine upgraded aTyr Pharma from a “strong sell” rating to a “sell” rating in a research report on Friday, September 15th. Piper Jaffray Companies began coverage on aTyr Pharma in a research report on Thursday, September 7th. They issued an “overweight” rating and a $7.00 target price for the company. Finally, BMO Capital Markets set a $4.00 price target on aTyr Pharma and gave the stock a “hold” rating in a research report on Tuesday, August 15th.

Shares of aTyr Pharma (NASDAQ:LIFE) opened at 5.05 on Monday. aTyr Pharma has a 1-year low of $2.10 and a 1-year high of $5.35. The company has a 50-day moving average of $3.43 and a 200-day moving average of $3.43. The firm’s market capitalization is $120.39 million.

aTyr Pharma (NASDAQ:LIFE) last issued its earnings results on Monday, August 14th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.06. Equities research analysts predict that aTyr Pharma will post ($2.18) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “aTyr Pharma, Inc. (LIFE) Receives Consensus Rating of “Hold” from Analysts” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/atyr-pharma-inc-life-receives-consensus-rating-of-hold-from-analysts/1602159.html.

In other news, Director Paul Schimmel acquired 94,336 shares of the company’s stock in a transaction on Thursday, August 31st. The shares were bought at an average cost of $2.65 per share, with a total value of $249,990.40. Following the purchase, the director now owns 40,440 shares of the company’s stock, valued at approximately $107,166. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John Mendlein acquired 37,736 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was purchased at an average cost of $2.65 per share, for a total transaction of $100,000.40. The disclosure for this purchase can be found here. 33.30% of the stock is owned by corporate insiders.

A hedge fund recently raised its stake in aTyr Pharma stock. Renaissance Technologies LLC raised its position in aTyr Pharma, Inc. (NASDAQ:LIFE) by 1.8% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 38,800 shares of the biotechnology company’s stock after acquiring an additional 700 shares during the period. Renaissance Technologies LLC owned approximately 0.16% of aTyr Pharma worth $136,000 at the end of the most recent reporting period. 46.66% of the stock is currently owned by institutional investors and hedge funds.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.